Compare Stocks: ASRT, EOLS, SPRY, and OVID

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
EOLS Evolus	$8.88	$7.04	$3.86 ▼ $9.12	$586.53M	1.35	1.18 million shs	1.06 million shs
OVID Ovid Therapeutics	$2.80 -4.4%	$2.58	$1.12 ▼ $3.11	$572.22M	0.21	1.54 million shs	1.67 million shs
SPRY ARS Pharmaceuticals	$5.89 -2.3%	$6.84	$4.91 ▼ $13.15	$599.67M	0.98	1.91 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	0.00%	0.00%	+0.26%	+103.46%
EOLS Evolus	0.00%	+5.84%	+47.26%	+35.37%	+17.15%
OVID Ovid Therapeutics	-4.44%	0.00%	+22.27%	+2.56%	+122.22%
SPRY ARS Pharmaceuticals	-2.32%	+6.90%	+1.03%	-35.06%	-56.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
EOLS Evolus	$8.88	$7.04	$3.86 ▼ $9.12	$586.53M	1.35	1.18 million shs	1.06 million shs
OVID Ovid Therapeutics	$2.80 -4.4%	$2.58	$1.12 ▼ $3.11	$572.22M	0.21	1.54 million shs	1.67 million shs
SPRY ARS Pharmaceuticals	$5.89 -2.3%	$6.84	$4.91 ▼ $13.15	$599.67M	0.98	1.91 million shs	1.19 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	0.00%	0.00%	+0.26%	+103.46%
EOLS Evolus	0.00%	+5.84%	+47.26%	+35.37%	+17.15%
OVID Ovid Therapeutics	-4.44%	0.00%	+22.27%	+2.56%	+122.22%
SPRY ARS Pharmaceuticals	-2.32%	+6.90%	+1.03%	-35.06%	-56.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	1.80	Reduce	$22.65	-3.62% Downside
EOLS Evolus	2.50	Moderate Buy	$14.50	63.29% Upside
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.71	104.08% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$28.20	378.78% Upside

Current Analyst Ratings Breakdown

Latest ASRT, EOLS, SPRY, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/25/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$25.00 ➝ $24.00
6/17/2026	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
6/15/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/1/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$118.71M	1.28	$0.02 per share	1,437.29	$14.63 per share	1.61
EOLS Evolus	$297.18M	1.97	N/A	N/A	($0.47) per share	-18.89
OVID Ovid Therapeutics	$7.25M	75.43	N/A	N/A	$1.07 per share	2.62
SPRY ARS Pharmaceuticals	$84.28M	6.95	N/A	N/A	$0.13 per share	45.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$30.38M	-$5.69	N/A	21.17	N/A	-34.94%	-38.72%	-13.32%	N/A
EOLS Evolus	-$51.64M	-$0.52	N/A	111.00	N/A	-10.85%	N/A	-13.00%	11/4/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	11/11/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest ASRT, EOLS, SPRY, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.52	1.82	1.57
EOLS Evolus	N/A	1.70	1.28
OVID Ovid Therapeutics	0.05	12.39	12.39
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
EOLS Evolus	90.69%
OVID Ovid Therapeutics	72.24%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	5.70%
EOLS Evolus	5.00%
OVID Ovid Therapeutics	7.00%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	6.46 million	6.09 million	Optionable
EOLS Evolus	170	66.05 million	62.75 million	Optionable
OVID Ovid Therapeutics	60	195.30 million	181.63 million	Optionable
SPRY ARS Pharmaceuticals	90	99.45 million	65.83 million	Optionable

ASRT, EOLS, SPRY, and OVID Headlines

Recent News About These Companies

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 28 at 8:56 PM | newsfilecorp.comN

ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

August 28 at 6:00 PM | globenewswire.com

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to a Securities Class Action Lawsuit - Contact the Firm Before Deadline on October 5, 2026 for Leadership Role

August 28 at 11:05 AM | newsfilecorp.comN

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

August 28 at 10:11 AM | globenewswire.com

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

August 28 at 8:22 AM | newsfilecorp.comN

Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026

August 27 at 12:56 AM | theglobeandmail.com

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 27 at 8:51 PM | newsfilecorp.comN

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

August 27 at 8:11 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

August 27 at 5:27 PM | prnewswire.com

ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

August 27 at 3:54 PM | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

August 27 at 12:00 PM | globenewswire.com

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

August 27 at 10:07 AM | prnewswire.com

ROSEN, A LEADING NATIONAL FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 26 at 8:46 PM | newsfilecorp.comN

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

August 26 at 4:44 PM | businesswire.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 5.9% - Here's Why

August 26 at 3:39 PM | marketbeat.com

Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Deadline on October 5, 2026

August 26 at 10:20 AM | newsfilecorp.comN

Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY

August 26 at 10:09 AM | prnewswire.com

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

August 26 at 9:49 AM | newsfilecorp.comN

ADAR1 Capital Management LLC Purchases Shares of 600,999 ARS Pharmaceuticals, Inc. $SPRY

August 26 at 3:03 AM | marketbeat.com

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026

August 25, 2026 | theglobeandmail.com

ROSEN, A LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

August 25, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, EOLS, SPRY, and OVID Company Descriptions

Assertio NASDAQ:ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Evolus NASDAQ:EOLS

$8.88 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Ovid Therapeutics NASDAQ:OVID

$2.80 -0.13 (-4.44%)

As of 08/28/2026 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

ARS Pharmaceuticals NASDAQ:SPRY

$5.89 -0.14 (-2.32%)

As of 08/28/2026 04:00 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, EOLS, SPRY, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, EOLS, SPRY, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, EOLS, SPRY, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, EOLS, SPRY, and OVID Company Descriptions

Assertio NASDAQ:ASRT

Evolus NASDAQ:EOLS

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, EOLS, SPRY, and OVID Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, EOLS, SPRY, and OVID Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, EOLS, SPRY, and OVID Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, EOLS, SPRY, and OVID Company Descriptions

Assertio NASDAQ:ASRT

Evolus NASDAQ:EOLS

Ovid Therapeutics NASDAQ:OVID

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools